Drug Profile

CV2CoV

Alternative Names: CV-2-CoV; CV2CoV - CureVac/GSK

Latest Information Update: 28 Apr 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator CureVac; GlaxoSmithKline
Developer CureVac; GSK
Class COVID-19 vaccines; RNA vaccines
Mechanism of Action Immunostimulants

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

No development reported COVID 2019 infections

Most Recent Events

28 Apr 2025 No recent reports of development identified for phase-I development in COVID-2019-infections(Prevention) in USA (IM, Injection)
07 Mar 2023 CureVac completes a phase I trial in COVID-2019 infections (Prevention) in USA (IM) (NCT05260437)
22 Apr 2022 Pharmacodynamics data from a preclinical study in COVID-2019 infections released by CureVac

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com